Brokers Offer Predictions for ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Ascendis Pharma A/S in a research report issued on Tuesday, February 25th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will earn ($2.72) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $200.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.34) per share.

ASND has been the subject of a number of other research reports. Wedbush reissued an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. UBS Group initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a report on Friday, November 15th. Finally, Oppenheimer reduced their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $202.36.

Remove Ads

Ascendis Pharma A/S Stock Down 3.0 %

Shares of Ascendis Pharma A/S stock traded down $4.65 during trading on Thursday, reaching $151.93. The company's stock had a trading volume of 581,902 shares, compared to its average volume of 448,058. The business's 50-day moving average price is $136.11 and its 200-day moving average price is $133.92. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $158.69. The firm has a market cap of $9.22 billion, a PE ratio of -21.40 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth about $28,000. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. Jones Financial Companies Lllp grew its holdings in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Blue Trust Inc. increased its position in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the period. Finally, Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.